AstraZeneca has been granted protection from future product liability claims related to its COVID-19 vaccine hopeful by most of the countries with which it has struck supply agreements, a senior executive told Reuters.
With 25 companies testing their vaccine candidates on humans and getting ready to immunise hundred millions of people once the products are shown to work, the question of who pays for any claims for damages in case of side effects has been a tricky point in supply negotiations.
“In the contracts we have in place, we are asking for indemnification. For most countries it is acceptable to take that risk on their shoulders because it is in their national interest,” he said, adding that Astra and regulators were making safety and tolerability a top priority.
The Recovery trial has steadfastly ignored Professor Didier Raoult and a string of countries that have implemented his protocol, early use of HCQ with Azythromycin in safe doses, despite the fact that, after treating 3,737 patients — the single largest study in the world —Raoult has lost only 0.6 per cent, while Horby and Landray are presiding over carnage —a fatality rate of 25 per cent.
- The Recovery trial has steadfastly ignored Professor Didier Raoult in the early use of HCQ with Azythromycin in safe doses.
- Raoult has lost only 0.6 per cent, while Horby and Landray are presiding over carnage —a fatality rate of 25 per cent.
- Landray admitted to an investigative journalist at FranceSoir ‘these are quite high doses to… have a chance of killing the virus.’ Or killing the patient.
- Recovery is not the only trial delivering dangerously elevated doses of HCQ to Covid patients. Dosage in the international Solidarity trial was four times greater than the dose being used in India.
- WHO has been working for years with Gilead Sciences trying to get the pharmaceutical company’s lacklustre drug Remdesivir to show efficacy at curing first Ebola, with poor results, and now Covid-19.
- Landray revealed Gilead pays scientists 20 to 50 times more to conduct a clinical trial than Horby and Landray were paid to conduct the Recovery trial.
- Horby is the executive director of the International Severe Acute Respiratory and Emerging Infection Consortium which received 4.5 million pounds for research into vaccines.
- Horby established the Epidemic Research Group which is promised up to 14 million pounds from AstraZeneca and Zuckerberg/Chan of Facebook fame for the development of a Covid-19 vaccine which is being trialled by Oxford University.
- AstraZeneca is interested in merging with Gilead Sciences, which, if it went through, would create the biggest Big Pharma ever.
- Horby and Landray have announced that dexamethasone, a low-cost steroid which is also being tested has reduced the mortality rate of Covid-19 patients on ventilators from a scandalous 41 per cent to a still appalling 32 per cent.
- Raoult has pointed out that in his hospital, of the 0.6 per cent who die, a mere 16 per cent were in ICU
- In Britain, where almost 42,000 people have died of Covid, the only thing randomised, controlled trials have achieved, is to blind people to the evidence that 40,000 of those deaths could have been avoided.
A British pharmaceutical giant is already manufacturing an unproven coronavirus vaccine as it hopes to dish out hundreds of millions of doses by September.
The Cambridge-based firm expects to have distributed hundreds of millions of doses of the vaccine this year and at least 2billion by mid-2021.
It has signed deals to produce 400million doses for the US and 100million for the UK if it is successful in human trials. Results are expected in August.
Britain has agreed to pay for the doses ‘as early as possible’ – with ministers hoping for a third of those to be ready for September if proven effective.
The Oxford University vaccine tipped as a “front runner” in the race to develop a coronavirus jab does not stop the virus in monkeys and may only be partially effective, experts have warned.
- All of the vaccinated monkeys treated with the Oxford vaccine became infected.
- Vaccine data suggests that the jab may not be able to prevent the spread of the virus between infected individuals.